Oman Investment Authority has invested in Neuralink as the brain-computer interface company accelerates human trials. By January 2026 the company had implanted devices in 21 patients with a target of 1000 procedures before year end.
Sovereign wealth funds are no longer content parking capital in conventional asset classes. Oman Investment Authority has announced an investment in Neuralink, the US-based neurotechnology company founded by Elon Musk, marking one of the more significant moves by a Gulf sovereign fund into the frontier of human-machine interface technology. The investment amount was not disclosed, but the decision itself carries considerable weight, both as a signal of where OIA sees long-term value and as a marker of how seriously Gulf states are now treating deep technology as an asset class worthy of sovereign capital.
Founded in 2016 and headquartered in the United States, Neuralink develops implantable brain-computer interface systems, ultra-precise neural devices designed to be surgically placed in the brain to enable direct communication between human neural activity and digital machines. The core application being developed is translating brain signals into digital commands, allowing users to control computers, type, and interact with devices through thought alone. The primary medical focus is on patients with neurological conditions including stroke, amyotrophic lateral sclerosis, and other neurodegenerative diseases that impair motor function while leaving cognitive ability largely intact.
The clinical progress behind this investment is real and accelerating. By January 2026, Neuralink had implanted its devices in 21 patients, 17 of whom received procedures during 2025 alone, reflecting a significant ramp in trial activity. The company has received US regulatory approval to conduct human trials using robotic surgical systems for implantation, and to date has recorded zero serious device-related adverse events. Its first human patient successfully operated a computer and typed using neural signals alone, which remains the most compelling public demonstration of the technology's practical potential. Neuralink's founder has set a target of 1,000 implant procedures before the end of 2026, an ambition that would represent a roughly 50-fold increase from where the program stands today.
The company is also developing a project called Blindsight, a neural visual prosthesis designed to restore limited vision by stimulating the brain's visual cortex using input from a digital camera. Human trials for that system are planned, with early versions expected to provide low-resolution visual perception for people who have lost their sight entirely. It is a second major product line that, if it reaches clinical viability, expands Neuralink's addressable patient population significantly beyond motor and communication disorders.
Neuralink's operating model is vertically integrated, covering research and development, implant manufacturing, robotic surgery systems, and specialized surgical teams entirely in-house. That structure is designed to accelerate development cycles and maintain control over safety and quality standards, but it also means the capital requirements are substantial and ongoing. OIA's investment fits into a portfolio that already spans more than 52 countries across deep tech, healthcare, and innovation-led sectors. The fund reported exceptional financial results in 2025 and has been steadily increasing its exposure to high-impact technology bets that align with long-horizon economic diversification goals.
For the broader MENA region, OIA's move joins a growing pattern of Gulf sovereign capital flowing into frontier neurotechnology and deep healthcare technology. Saudi Arabia and the UAE have both made healthcare innovation central to their national transformation agendas, and the appetite among regional institutional investors for breakthrough medical technology has grown considerably as those agendas have matured. Neuralink's intersection of neuroscience, robotics, and AI places it firmly within the kind of technology trajectory that Gulf sovereign funds are increasingly willing to back early, before commercial viability is fully established, in exchange for exposure to what could become transformative medical infrastructure over the coming decade.
